Gonadotropins - Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)

FSH and LH: The Hormones Controlling Testosterone Production and Fertility

Dr. Matt and Dr. Mike deliver an educational breakdown of gonadotropins that has attracted 603K views, largely because understanding FSH and LH is essential for anyone trying to make sense of testosterone therapy, fertility, and hormonal health. These two hormones are the messengers that connect the brain to the gonads, and without understanding them, testosterone levels and sperm counts are just isolated numbers without context. This is the foundational biology that makes TRT decisions, fertility protocols, and hormone optimization strategies actually make sense.

Gonadotropins are glycoprotein hormones produced by the anterior pituitary gland in response to gonadotropin-releasing hormone (GnRH) from the hypothalamus. There are two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Despite being produced by the same gland in response to the same upstream signal, they have distinct functions in the reproductive system. Understanding what each one does, what regulates it, and what happens when levels are abnormal is the key to interpreting your hormonal bloodwork and understanding why certain treatments work the way they do.

Luteinizing Hormone: The Testosterone Signal

LH is the primary hormonal signal that tells the Leydig cells in the testes to produce testosterone. When the hypothalamus releases GnRH in pulses (pulsatile release is critical, as continuous GnRH actually suppresses LH), the anterior pituitary responds by releasing LH into the bloodstream. LH travels to the testes, binds to LH receptors on Leydig cells, and activates the enzymatic cascade that converts cholesterol into testosterone through a series of biochemical steps.

The testosterone produced by Leydig cells then enters the bloodstream and feeds back to both the hypothalamus and the pituitary. High testosterone levels suppress GnRH release (hypothalamic feedback) and reduce pituitary sensitivity to GnRH (pituitary feedback). This negative feedback loop maintains testosterone levels within a physiological range. When testosterone drops, the brake is released, GnRH increases, LH rises, and testosterone production is stimulated. When testosterone rises, the brake is applied, GnRH decreases, LH drops, and production slows.

This feedback mechanism is why exogenous testosterone replacement suppresses natural production. When you inject testosterone, the hypothalamus and pituitary detect the elevated testosterone and reduce GnRH and LH output. The Leydig cells, no longer receiving adequate LH stimulation, reduce their testosterone production and can even atrophy (shrink) over time. This is also why testicular size decreases in many men on TRT: without LH stimulation, the Leydig cells and the testes as a whole become smaller.

Follicle-Stimulating Hormone: The Fertility Signal

FSH's primary function in males is supporting spermatogenesis, the production of sperm cells. FSH acts on Sertoli cells in the seminiferous tubules of the testes. Sertoli cells are often described as "nurse cells" for developing sperm because they provide structural support, nutrition, and the hormonal microenvironment necessary for sperm maturation. Without adequate FSH stimulation, Sertoli cell function declines, and sperm production drops.

The feedback regulation of FSH involves a hormone called inhibin B, produced by Sertoli cells. When spermatogenesis is proceeding normally and Sertoli cells are healthy, they produce inhibin B, which feeds back to the pituitary and suppresses FSH secretion. When spermatogenesis is impaired or Sertoli cell function is compromised, inhibin B drops, and FSH rises as the pituitary attempts to stimulate more activity. This is why elevated FSH in a man with low sperm count suggests primary testicular damage: the pituitary is trying harder because the testes are not responding.

In the context of TRT, FSH is suppressed along with LH by the negative feedback from exogenous testosterone. Without FSH, Sertoli cells lose their stimulation, and spermatogenesis declines or stops. This is the mechanistic explanation for TRT-induced infertility. It is not a side effect in the traditional sense. It is a predictable consequence of the feedback system functioning as designed.

Clinical Significance: Reading Your Lab Results

Understanding the relationship between LH, FSH, and testosterone transforms how you interpret hormonal bloodwork. The patterns tell a story about where the problem lies in the reproductive axis.

Low testosterone with high LH and FSH indicates primary hypogonadism. The testes are failing to produce adequate testosterone despite receiving strong signals from the pituitary. The pituitary is compensating by releasing more gonadotropins, but the testes cannot respond. Causes include testicular damage, Klinefelter syndrome, and age-related Leydig cell decline. In this situation, the problem is at the gonadal level, and stimulating the pituitary further (with clomiphene, for example) may not produce adequate testosterone improvement because the testes have limited capacity to respond.

Low testosterone with low or normal LH and FSH indicates secondary (or central) hypogonadism. The testes could produce more testosterone, but they are not receiving adequate stimulation. The problem is upstream, at the hypothalamus or pituitary. Causes include pituitary tumors, head trauma, opioid use, obesity (which suppresses GnRH through multiple mechanisms), and excessive stress or overtraining. In this situation, treatments that stimulate the pituitary (clomiphene, hCG) or restore hypothalamic function (addressing the underlying cause) can often increase testosterone without requiring direct replacement.

Normal testosterone with abnormal FSH can indicate isolated fertility issues. A man with normal testosterone but elevated FSH and low sperm count likely has a problem specific to the seminiferous tubules or Sertoli cells while his Leydig cells (testosterone production) are functioning adequately. This pattern guides treatment toward fertility-specific interventions rather than testosterone replacement.

Therapeutic Applications of Gonadotropin Knowledge

The practical applications of understanding FSH and LH extend directly to treatment decisions. HCG (human chorionic gonadotropin) mimics LH. It binds to the same receptor on Leydig cells and stimulates testosterone production. This is why HCG is used alongside or instead of testosterone to maintain testicular function and size during TRT, and why it can support fertility by keeping the Leydig cells active and the testes from atrophying.

Clomiphene citrate works by blocking estrogen receptors in the hypothalamus, reducing the negative feedback signal from estradiol. The hypothalamus, "thinking" estrogen is lower than it actually is, increases GnRH output. This raises both LH and FSH from the pituitary, simultaneously increasing testosterone (through LH acting on Leydig cells) and supporting spermatogenesis (through FSH acting on Sertoli cells). This dual effect is why clomiphene is the preferred treatment for men who want both higher testosterone and preserved fertility.

Recombinant FSH (follitropin) can be prescribed directly to men with isolated FSH deficiency causing infertility. This is a more targeted approach than clomiphene when the specific problem is inadequate FSH rather than a general deficiency in gonadotropin signaling. It is commonly used in conjunction with HCG, with HCG providing the LH-like stimulation for testosterone and FSH providing the spermatogenesis support.

Why This Knowledge Changes Your Approach to Hormonal Health

The practical value of understanding FSH and LH is that it transforms hormonal health from a single-number focus ("my testosterone is X") into a systems-level understanding. Testosterone is the output of a regulatory system that involves the hypothalamus, pituitary, and gonads working in concert. When something goes wrong, knowing where in the system the dysfunction lies determines what treatment makes sense.

For men considering TRT, understanding the feedback loop explains why you might choose clomiphene or HCG over testosterone if fertility is a priority. It explains why testicular atrophy occurs during TRT and what can be done to mitigate it. It explains why stopping TRT can lead to a period of very low testosterone as the suppressed axis slowly recovers. And it explains why some men recover their natural production after stopping TRT while others do not: the extent of axis suppression and the underlying health of each component determine the recovery trajectory.

For women (who also have LH and FSH regulating their reproductive systems), the same principles apply in the context of ovarian function. LH triggers ovulation and supports the corpus luteum's progesterone production. FSH drives follicular development. The feedback mechanisms involving estradiol and progesterone parallel the testosterone feedback in men. This shared framework is why the gonadotropin system is sometimes called the master regulator of reproductive function across both sexes.

Dr. Matt and Dr. Mike succeed in making this complex endocrinology accessible because they consistently connect the biochemistry to clinical scenarios. Understanding that LH drives testosterone production is abstract knowledge. Understanding that your low LH explains why clomiphene might raise your testosterone without requiring injections is practical, actionable knowledge that directly affects treatment decisions. That translation from mechanism to application is what makes gonadotropin education genuinely valuable for anyone navigating hormonal health.

For men already on TRT who want to add fertility preservation, understanding the gonadotropin system reveals why simply adding HCG to a testosterone protocol helps maintain testicular function but may not fully restore spermatogenesis. HCG replaces the LH signal but does nothing for FSH. Adding recombinant FSH or switching to clomiphene (which raises both LH and FSH) may be necessary for men who need to optimize sperm production while maintaining adequate testosterone levels. This nuanced approach requires a provider who understands the full gonadotropin cascade and can design protocols that address both the testosterone and fertility sides of the equation simultaneously rather than treating them as separate, unrelated problems.

Clinical Data on Gonadotropin Levels and TRT Management

Understanding gonadotropin physiology has direct clinical applications. A 2010 study in the Journal of Clinical Endocrinology and Metabolism measured LH pulse frequency in healthy men across age groups and found that LH pulsatility decreases by approximately 25% between ages 30 and 60, contributing to the age-related decline in testosterone. The Endocrine Society Clinical Practice Guideline for testosterone therapy, updated in 2018, recommends measuring both LH and FSH alongside testosterone to differentiate primary hypogonadism (testicular failure, with elevated LH/FSH) from secondary hypogonadism (pituitary/hypothalamic failure, with low or inappropriately normal LH/FSH). This distinction matters because secondary hypogonadism is potentially reversible and may respond to clomiphene citrate or hCG rather than requiring exogenous testosterone. A 2013 randomized trial published in the Journal of Clinical Endocrinology and Metabolism tested hCG monotherapy in hypogonadal men and found that 3,000 IU twice weekly increased testosterone levels by an average of 49% while maintaining sperm production, compared to testosterone injections which suppressed sperm counts by 90% or more within 6 months. For men concerned about fertility while addressing low testosterone, this gonadotropin-based approach offers a meaningful alternative.